GLPwatch
Bydureon vs Xultophy
Drug comparison
Last updated 2026-05-28 15:46 UTCBydureon (exenatide by AstraZeneca) and Xultophy (liraglutide by Novo Nordisk) are both injectable medications for type 2 diabetes. Bydureon uses the active ingredient exenatide, while Xultophy combines liraglutide with insulin degludec. Both are given as subcutaneous injections, but Bydureon is taken once weekly, whereas Xultophy is taken once daily.
AI summary of the sources below.
| Bydureon | Xultophy | |
|---|---|---|
| Active ingredient | exenatide | liraglutide |
| Manufacturer | astrazeneca | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | type 2 diabetes |
| Label updated | — | 2025-10-14 |